MDV3100 for the treatment of prostate cancer

被引：26

作者：

Mukherji, Deborah

Pezaro, Carmel J.

De-Bono, Johann S. ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2012年 / 21卷 / 02期

关键词：

abiraterone; alpharadin; cabazitaxel; MDV3100; prostate cancer; Sipuleucel-T; COMBINED ANDROGEN BLOCKADE; CIRCULATING TUMOR-CELLS; ANTIANDROGEN WITHDRAWAL; METASTATIC CARCINOMA; SERUM PHOSPHATASES; STEROID-SYNTHESIS; CASTRATION; RECEPTOR; TRIAL; GENE;

D O I：

10.1517/13543784.2012.651125

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with docetaxel chemotherapy. Drug development for advanced prostate cancer is advancing at a rapid pace with four other novel therapies (abiraterone, cabazitaxel, alpharadin and sipuleucel-T) also shown to improve overall survival in large randomised studies. Areas covered: This review will cover the historical background of androgen deprivation therapy, recently approved agents for advanced prostate cancer, an overview of the clinical development of MDV3100 and an analysis of how MDV3100 may fit into future treatment protocols for this disease. Expert opinion: Full analysis of safety and efficacy data is awaited; however, MDV3100 appears to be a well-tolerated addition to the expanding portfolio of effective drugs for the treatment of advanced prostate cancer.

引用

页码：227 / 233

页数：7

共 43 条

[1] Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival [J].